Tenaya Therapeutics, Inc.

NASDAQ: TNYA · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001858848Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 47DQ —GM —SS 47

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

$1.3M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$90.6M

Employees

as of 2026-08-14

Market cap

$159.1M

as of 2026-08-14

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$90.6M-$90.6M2025

Operating income-$93.3M-$93.3M2025

Total assets$146.9M$146.9M2025

Liabilities$23.7M$23.7M2025

Equity$123.3M$123.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Tenaya Therapeutics, Inc.’s financial profile?

Tenaya Therapeutics, Inc. earned -$90.6M in FY2025 net income.

Peers · Healthcare

Acumen Pharmaceuticals, Inc.——Organigram Global Inc.——Conexeu Sciences Inc.——Armata Pharmaceuticals, Inc.——Canton Strategic Holdings Inc——Indaptus Therapeutics, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOFaraz Ali

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: TNYA

Employees70

IPO date2021-07-30

Latest filings

8-K2026-08-05 10-Q2026-08-05 8-K2026-07-02 8-K2026-06-29 8-K2026-05-29 10-Q2026-05-06 8-K2026-05-06 DEF 14A2026-04-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.